- Status:
- Red
- Decision Date:
- October 2023
Comments
RED: NICE TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NHSE commissioned (Decision date - November 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
